RU2666255C2 - Метилглиоксаль в качестве маркера злокачественной опухоли - Google Patents

Метилглиоксаль в качестве маркера злокачественной опухоли Download PDF

Info

Publication number
RU2666255C2
RU2666255C2 RU2015119512A RU2015119512A RU2666255C2 RU 2666255 C2 RU2666255 C2 RU 2666255C2 RU 2015119512 A RU2015119512 A RU 2015119512A RU 2015119512 A RU2015119512 A RU 2015119512A RU 2666255 C2 RU2666255 C2 RU 2666255C2
Authority
RU
Russia
Prior art keywords
malignant
tumor
patients
blood
subjects
Prior art date
Application number
RU2015119512A
Other languages
English (en)
Russian (ru)
Other versions
RU2015119512A (ru
Inventor
Доминик БЕЛЬПОММ
Филипп ИРИГАРЕ
Original Assignee
Ассосьясьон Пур Ля Решерш Терапетик Анти-Кансерез
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ассосьясьон Пур Ля Решерш Терапетик Анти-Кансерез filed Critical Ассосьясьон Пур Ля Решерш Терапетик Анти-Кансерез
Publication of RU2015119512A publication Critical patent/RU2015119512A/ru
Application granted granted Critical
Publication of RU2666255C2 publication Critical patent/RU2666255C2/ru

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
RU2015119512A 2012-10-25 2013-10-25 Метилглиоксаль в качестве маркера злокачественной опухоли RU2666255C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2012/071163 2012-10-25
PCT/EP2012/071163 WO2014063743A1 (en) 2012-10-25 2012-10-25 Methylglyoxal as a marker of cancer
PCT/EP2013/072459 WO2014064283A1 (en) 2012-10-25 2013-10-25 Methylglyoxal as a marker of cancer

Publications (2)

Publication Number Publication Date
RU2015119512A RU2015119512A (ru) 2016-12-20
RU2666255C2 true RU2666255C2 (ru) 2018-09-06

Family

ID=47074733

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015119512A RU2666255C2 (ru) 2012-10-25 2013-10-25 Метилглиоксаль в качестве маркера злокачественной опухоли

Country Status (11)

Country Link
US (1) US20150301056A1 (https=)
JP (1) JP6543193B2 (https=)
CN (1) CN104854458B (https=)
CA (1) CA2889110A1 (https=)
DK (1) DK2912465T3 (https=)
ES (1) ES2656896T3 (https=)
MA (1) MA38042B2 (https=)
PT (1) PT2912465T (https=)
RU (1) RU2666255C2 (https=)
TN (1) TN2015000161A1 (https=)
WO (2) WO2014063743A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106769349B (zh) * 2017-01-06 2020-01-21 上海君联医疗设备有限公司 血液中异常糖基化蛋白细胞的检测方法
CN108426996B (zh) * 2017-02-15 2020-09-15 江苏美正生物科技有限公司 一种3-甲基喹噁啉-2-羧酸残留的快速检测试剂盒及其制备方法和应用
GB2566681B (en) * 2017-09-14 2021-07-28 Ip2Ipo Innovations Ltd Biomarker
CN108061802A (zh) * 2017-12-08 2018-05-22 武汉科技大学 一种通过血液检测评定乳腺癌的方法
SG11202104101TA (en) * 2018-11-28 2021-05-28 Nat Univ Singapore Method of detecting cancer and/or tuberculosis
CN110604823B (zh) * 2019-10-21 2020-10-20 兰州大学 一种快速筛选抗糖化和/或抗衰老物质的方法
CN113376199A (zh) * 2021-05-12 2021-09-10 兰立生物科技(苏州)有限公司 一种用于癌症检测的生化分析检测系统
CN114496306B (zh) * 2022-01-28 2022-12-20 北京大学口腔医学院 基于机器学习的预后生存阶段预测方法和系统
US20220206017A1 (en) * 2022-03-18 2022-06-30 Joel Steven Goldberg Aerobic glycolysis and hypermetabolic states

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2007073005A1 (ja) * 2005-12-22 2009-06-04 学校法人慶應義塾 メチル基転移反応調節物質
US8026049B2 (en) * 2007-03-23 2011-09-27 Wisconsin Alumni Research Foundation Noninvasive measurement and identification of biomarkers in disease state
JP4836926B2 (ja) * 2007-11-12 2011-12-14 株式会社日本トリム 糖分解代謝物の測定方法
JP5787339B2 (ja) * 2009-12-28 2015-09-30 学校法人福岡大学 糖尿病前症の検査方法
KR20140024860A (ko) * 2011-02-24 2014-03-03 버밀리언, 인코포레이티드 난소암에 대한 바이오마커 패널，진단 방법 및 시험 키트

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANTOGNELLI C. et al. Overexpression of glyoxalase system enzymes in human kidney tumor // Cancer J. 2006, Vol.12, No.3, P.222-228. *
BISWAS U.K. et al. Elevation of serum methylglyoxal may be used as a screening marker in oral premalignant lesions // Biomedical Research. 2011, Vol.22, No.3, P.273. *
BISWAS U.K. et al. Elevation of serum methylglyoxal may be used as a screening marker in oral premalignant lesions // Biomedical Research. 2011, Vol.22, No.3, P.273. MATSUURA T. et al. Studies on Methylglyoxal. II. : Changes of Methylglyoxal Level Accompanying the Changes of Glyoxalase I and II Activities in Mice Bearing L1210 Leukemia and Sarcoma 180 // Chemical and Pharmaceutical Bulletin. 1986, Vol.34, No.7, P.2926-2930. ANTOGNELLI C. et al. Overexpression of glyoxalase system enzymes in human kidney tumor // Cancer J. 2006, Vol.12, No.3, P.222-228. OYA-ITO T. et al. Heat-shock protein 27 (Hsp27) as a target of methylglyoxal in gastrointestinal cancer // Biochim Biophys Acta. 2011. Vol.1812, No.7, P.769-781. SYNOLD T. et al. Advanced glycation end products of DNA: quantification of N2-(1-Carboxyethyl)-2'-deoxyguanosine in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry // Chem Res Toxicol. 2008, Vol.21, No.11, P.2148-2155. *
MATSUURA T. et al. Studies on Methylglyoxal. II. : Changes of Methylglyoxal Level Accompanying the Changes of Glyoxalase I and II Activities in Mice Bearing L1210 Leukemia and Sarcoma 180 // Chemical and Pharmaceutical Bulletin. 1986, Vol.34, No.7, P.2926-2930. *
OYA-ITO T. et al. Heat-shock protein 27 (Hsp27) as a target of methylglyoxal in gastrointestinal cancer // Biochim Biophys Acta. 2011. Vol.1812, No.7, P.769-781. *
SYNOLD T. et al. Advanced glycation end products of DNA: quantification of N2-(1-Carboxyethyl)-2'-deoxyguanosine in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry // Chem Res Toxicol. 2008, Vol.21, No.11, P.2148-2155. *

Also Published As

Publication number Publication date
CN104854458B (zh) 2018-02-09
CA2889110A1 (en) 2014-05-01
JP6543193B2 (ja) 2019-07-10
MA38042A3 (fr) 2018-03-30
CN104854458A (zh) 2015-08-19
RU2015119512A (ru) 2016-12-20
US20150301056A1 (en) 2015-10-22
MA38042B2 (fr) 2019-11-29
JP2016500821A (ja) 2016-01-14
DK2912465T3 (en) 2018-01-15
ES2656896T3 (es) 2018-02-28
MA38042A2 (fr) 2017-02-28
WO2014063743A1 (en) 2014-05-01
PT2912465T (pt) 2018-01-25
TN2015000161A1 (en) 2016-10-03
WO2014064283A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
RU2666255C2 (ru) Метилглиоксаль в качестве маркера злокачественной опухоли
Park et al. Metabolomic-derived novel cyst fluid biomarkers for pancreatic cysts: glucose and kynurenine
Jung et al. Tissue metabolite profiling identifies differentiating and prognostic biomarkers for prostate carcinoma
US10509034B2 (en) Bladder carcinoma biomarkers
JP2018518683A (ja) バイオマーカーパネルに基づいて対象における膵癌を診断するための手段および方法
US20210270836A1 (en) Method for the in vitro diagnosis of prostate cancer by means of urinary biomarkers
Skorupa et al. Grading of endometrial cancer using 1H HR-MAS NMR-based metabolomics
US10697968B2 (en) Lipid markers for early diagnosis of breast cancer
Wang et al. The urinary sarcosine/creatinine ratio is a potential diagnostic and prognostic marker in prostate cancer
Sato et al. Accurate quantification of urinary metabolites for predictive models manifest clinicopathology of renal cell carcinoma
CN106370744A (zh) 8‑羟基脱氧鸟苷作为尿液标志物的应用
Samir et al. Assessment of hematological parameters, enzymes activities, and oxidative stress‎ markers in salivary and blood of Algerian breast cancer patients receiving‎ chemotherapy
CN102105797A (zh) 用于评估过氧化物酶体增殖的工具和方法
Buszewska-Forajta et al. Untargeted metabolomics study of three matrices: seminal fluid, urine, and serum to search the potential indicators of prostate cancer
Demir et al. Diagnostic and prognostic value of tumor M2-pyruvate kinase levels in patients with colorectal cancer
US20180164320A1 (en) Method for diagnosis of colorectal cancer using mass spectrometry of n-glycans
KR102713301B1 (ko) 췌장암 및 췌장관 내 유두상 점액성 종양의 마커
Dahpy et al. Evaluation of tripartite motif 59 and its diagnostic utility in benign bowel diseases and colorectal cancer
EP2912465B1 (en) Methylglyoxal as a marker of cancer
Deng et al. Nanotrap-enabled quantification of KRAS-induced peptide hydroxylation in blood for cancer early detection
OA17290A (en) Methylglyoxal as marker of cancer.
Tan et al. Identifying Prostaglandin D2 Synthase in Urine: A Potential Biomarker for Bladder Cancer
JP5794511B2 (ja) オートタキシン測定による膵疾患の検査方法および検査薬
Zhang et al. Gastric juice ZC3H13 as a potential biomarker for gastric cancer
Sousa MALDI-TOF MS-based urinary proteomic/peptidomic signature of breast cancer as innovative diagnostic approach